Radioimmunoguided surgery after primary treatment of locally advanced breast cancer

P. Percivale, S. Bertogllo, P. Meszaros, G. Canavese, F. Cafiero, M. Gipponi, E. Campora, M. Gasco, F. Badellino

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: To assess the role of radioimmunoguided surgery (RIGS) using a handheld intraoperative gamma-detecting probe (GDP) to identify neoplastic disease after primary chemotherapy in locally advanced breast cancer (LABC) patients injected with iodine 125-labeled monoclonal antibodies (MAbs). Patients and Methods: Twenty-one patients with histologically documented LABC were treated with a combined modality approach. After three courses of primary chemotherapy and before modified radical mastectomy, the 125I- radiolabeled MAbs B72.3 (anti-TAG72) and FO23C5 (anticarcinoembryonic antigen [CEA]) were administered to 11 patients (group A) and 10 patients (group B), respectively. At surgery, a GDP was used to locate the primary tumor and to assess possible tumor multicentricity and the presence of ipsilateral axillary metastases. Routine pathologic examination was performed in neoplastic and normal tissue specimens of all 21 patients. In addition, immunohistochemical assay for TAG72 and CEA expression was performed. Results: In group A patients, RIGS identified primary tumor in seven of 11 patients (63.3%) and unpalpable multicentric tumor lesions were located in two of four (50%). Positive axillary lymph nodes were histologically documented in eight of 11 patients (72.7%) and RIGS identified three of eight (37.5%). In group B, RIGS located the primary tumor lesion in four of 10 patients (40%); in two cases, the tumor was not clinically evident. Multicentricity was observed in one of two patients and lymph node involvement in three of nine (33.3%). No false-positive results were observed in either group A or B. Conclusion: RIGS appears to be a safe and reliable technique. However, the MAbs used in this study are not sufficiently specific. RIGS represents a technique for which the full potential for intraoperative assessment of breast cancer lesions can be reached when more specific antibodies become readily available.

Original languageEnglish
Pages (from-to)1599-1603
Number of pages5
JournalJournal of Clinical Oncology
Volume14
Issue number5
Publication statusPublished - May 1996

Fingerprint

Breast Neoplasms
Therapeutics
Neoplasms
Monoclonal Antibodies
Lymph Nodes
Modified Radical Mastectomy
Drug Therapy
Iodine
Neoplasm Metastasis
Antigens
Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Percivale, P., Bertogllo, S., Meszaros, P., Canavese, G., Cafiero, F., Gipponi, M., ... Badellino, F. (1996). Radioimmunoguided surgery after primary treatment of locally advanced breast cancer. Journal of Clinical Oncology, 14(5), 1599-1603.

Radioimmunoguided surgery after primary treatment of locally advanced breast cancer. / Percivale, P.; Bertogllo, S.; Meszaros, P.; Canavese, G.; Cafiero, F.; Gipponi, M.; Campora, E.; Gasco, M.; Badellino, F.

In: Journal of Clinical Oncology, Vol. 14, No. 5, 05.1996, p. 1599-1603.

Research output: Contribution to journalArticle

Percivale, P, Bertogllo, S, Meszaros, P, Canavese, G, Cafiero, F, Gipponi, M, Campora, E, Gasco, M & Badellino, F 1996, 'Radioimmunoguided surgery after primary treatment of locally advanced breast cancer', Journal of Clinical Oncology, vol. 14, no. 5, pp. 1599-1603.
Percivale P, Bertogllo S, Meszaros P, Canavese G, Cafiero F, Gipponi M et al. Radioimmunoguided surgery after primary treatment of locally advanced breast cancer. Journal of Clinical Oncology. 1996 May;14(5):1599-1603.
Percivale, P. ; Bertogllo, S. ; Meszaros, P. ; Canavese, G. ; Cafiero, F. ; Gipponi, M. ; Campora, E. ; Gasco, M. ; Badellino, F. / Radioimmunoguided surgery after primary treatment of locally advanced breast cancer. In: Journal of Clinical Oncology. 1996 ; Vol. 14, No. 5. pp. 1599-1603.
@article{419a2ab507c14d2dad501fcde521eca4,
title = "Radioimmunoguided surgery after primary treatment of locally advanced breast cancer",
abstract = "Purpose: To assess the role of radioimmunoguided surgery (RIGS) using a handheld intraoperative gamma-detecting probe (GDP) to identify neoplastic disease after primary chemotherapy in locally advanced breast cancer (LABC) patients injected with iodine 125-labeled monoclonal antibodies (MAbs). Patients and Methods: Twenty-one patients with histologically documented LABC were treated with a combined modality approach. After three courses of primary chemotherapy and before modified radical mastectomy, the 125I- radiolabeled MAbs B72.3 (anti-TAG72) and FO23C5 (anticarcinoembryonic antigen [CEA]) were administered to 11 patients (group A) and 10 patients (group B), respectively. At surgery, a GDP was used to locate the primary tumor and to assess possible tumor multicentricity and the presence of ipsilateral axillary metastases. Routine pathologic examination was performed in neoplastic and normal tissue specimens of all 21 patients. In addition, immunohistochemical assay for TAG72 and CEA expression was performed. Results: In group A patients, RIGS identified primary tumor in seven of 11 patients (63.3{\%}) and unpalpable multicentric tumor lesions were located in two of four (50{\%}). Positive axillary lymph nodes were histologically documented in eight of 11 patients (72.7{\%}) and RIGS identified three of eight (37.5{\%}). In group B, RIGS located the primary tumor lesion in four of 10 patients (40{\%}); in two cases, the tumor was not clinically evident. Multicentricity was observed in one of two patients and lymph node involvement in three of nine (33.3{\%}). No false-positive results were observed in either group A or B. Conclusion: RIGS appears to be a safe and reliable technique. However, the MAbs used in this study are not sufficiently specific. RIGS represents a technique for which the full potential for intraoperative assessment of breast cancer lesions can be reached when more specific antibodies become readily available.",
author = "P. Percivale and S. Bertogllo and P. Meszaros and G. Canavese and F. Cafiero and M. Gipponi and E. Campora and M. Gasco and F. Badellino",
year = "1996",
month = "5",
language = "English",
volume = "14",
pages = "1599--1603",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Radioimmunoguided surgery after primary treatment of locally advanced breast cancer

AU - Percivale, P.

AU - Bertogllo, S.

AU - Meszaros, P.

AU - Canavese, G.

AU - Cafiero, F.

AU - Gipponi, M.

AU - Campora, E.

AU - Gasco, M.

AU - Badellino, F.

PY - 1996/5

Y1 - 1996/5

N2 - Purpose: To assess the role of radioimmunoguided surgery (RIGS) using a handheld intraoperative gamma-detecting probe (GDP) to identify neoplastic disease after primary chemotherapy in locally advanced breast cancer (LABC) patients injected with iodine 125-labeled monoclonal antibodies (MAbs). Patients and Methods: Twenty-one patients with histologically documented LABC were treated with a combined modality approach. After three courses of primary chemotherapy and before modified radical mastectomy, the 125I- radiolabeled MAbs B72.3 (anti-TAG72) and FO23C5 (anticarcinoembryonic antigen [CEA]) were administered to 11 patients (group A) and 10 patients (group B), respectively. At surgery, a GDP was used to locate the primary tumor and to assess possible tumor multicentricity and the presence of ipsilateral axillary metastases. Routine pathologic examination was performed in neoplastic and normal tissue specimens of all 21 patients. In addition, immunohistochemical assay for TAG72 and CEA expression was performed. Results: In group A patients, RIGS identified primary tumor in seven of 11 patients (63.3%) and unpalpable multicentric tumor lesions were located in two of four (50%). Positive axillary lymph nodes were histologically documented in eight of 11 patients (72.7%) and RIGS identified three of eight (37.5%). In group B, RIGS located the primary tumor lesion in four of 10 patients (40%); in two cases, the tumor was not clinically evident. Multicentricity was observed in one of two patients and lymph node involvement in three of nine (33.3%). No false-positive results were observed in either group A or B. Conclusion: RIGS appears to be a safe and reliable technique. However, the MAbs used in this study are not sufficiently specific. RIGS represents a technique for which the full potential for intraoperative assessment of breast cancer lesions can be reached when more specific antibodies become readily available.

AB - Purpose: To assess the role of radioimmunoguided surgery (RIGS) using a handheld intraoperative gamma-detecting probe (GDP) to identify neoplastic disease after primary chemotherapy in locally advanced breast cancer (LABC) patients injected with iodine 125-labeled monoclonal antibodies (MAbs). Patients and Methods: Twenty-one patients with histologically documented LABC were treated with a combined modality approach. After three courses of primary chemotherapy and before modified radical mastectomy, the 125I- radiolabeled MAbs B72.3 (anti-TAG72) and FO23C5 (anticarcinoembryonic antigen [CEA]) were administered to 11 patients (group A) and 10 patients (group B), respectively. At surgery, a GDP was used to locate the primary tumor and to assess possible tumor multicentricity and the presence of ipsilateral axillary metastases. Routine pathologic examination was performed in neoplastic and normal tissue specimens of all 21 patients. In addition, immunohistochemical assay for TAG72 and CEA expression was performed. Results: In group A patients, RIGS identified primary tumor in seven of 11 patients (63.3%) and unpalpable multicentric tumor lesions were located in two of four (50%). Positive axillary lymph nodes were histologically documented in eight of 11 patients (72.7%) and RIGS identified three of eight (37.5%). In group B, RIGS located the primary tumor lesion in four of 10 patients (40%); in two cases, the tumor was not clinically evident. Multicentricity was observed in one of two patients and lymph node involvement in three of nine (33.3%). No false-positive results were observed in either group A or B. Conclusion: RIGS appears to be a safe and reliable technique. However, the MAbs used in this study are not sufficiently specific. RIGS represents a technique for which the full potential for intraoperative assessment of breast cancer lesions can be reached when more specific antibodies become readily available.

UR - http://www.scopus.com/inward/record.url?scp=0029874670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029874670&partnerID=8YFLogxK

M3 - Article

C2 - 8622077

AN - SCOPUS:0029874670

VL - 14

SP - 1599

EP - 1603

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -